EXOCRINE PANCREAS CARCINOMA
Clinical trials for EXOCRINE PANCREAS CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXOCRINE PANCREAS CARCINOMA trials appear
Sign up with your email to follow new studies for EXOCRINE PANCREAS CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets Hard-to-Treat cancers with RAS mutations
Disease control OngoingThis study tests a combination of two targeted drugs, palbociclib and binimetinib, in people with cancers that have RAS mutations (like certain ovarian and pancreatic cancers). The goal is to see if the combo can slow tumor growth better than one drug alone. About 199 adults will…
Matched conditions: EXOCRINE PANCREAS CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…
Matched conditions: EXOCRINE PANCREAS CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 03:11 UTC